港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

生物医药B类股

719.918

+3.9520.55%

涨家数：15

跌家数：15

平家数：4

市盈率：- -

高：728.504

开：715.966

低：704.159

收：715.966

成交量：1.03亿

成交额：37.60亿

市值：4,603.13亿

流通市值：4,086.12亿

数据加载中...

总览新闻资讯

捕捉全球医药创新机遇，借道专业工具把握“新质生产力”投资主线

中国首个三组分百白破疫苗获批，康希诺生物成长逻辑跃升

仿制药药企，却搭上了创新药的东风

心玮医疗－Ｂ(06609)股价下跌8.532%，现价港币$53.6

阿斯达克财经

康方生物(09926)出现大手卖出4.8万股，成交价$138.4，涉资664.32万

阿斯达克财经

“明星”抗癌药中国“七连发”：跨国药企加速重塑在华商业模式

21世纪经济报道

国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作

国家医保局

加速布局儿童实体瘤治疗领域！亚盛医药 MDM2-p53 抑制剂APG-115获CDE纳入"星光计划"

港股劲方医药-B盘中涨超22%

每日经济新闻

港股异动 | 绿叶制药(02186)午前涨近3% 近日自研创新药LY03020中国Ⅱ期临床试验完成首例受试者入组

数万年前的“资阳人”被爆患有牙病四川资阳用十年造出一口好“牙”丨城市经济学

四川日报网

港股异动 | 再鼎医药(09688)涨超3% 近日与安进达成全球临床合作 Zoci正处于全球注册性临床III期阶段

归创通桥公布授出40万份购股权

谁在“裸泳”，谁有“余粮”？医械行业2025业绩加速分化

21世纪经济报道

亿腾嘉和(06998)4月13日斥资139.7万港元回购46.25万股

北京“创新医药32条”：突出原始创新，打通手术机器人入院堵点

归创通桥(02190)4月13日耗资281.725万港元回购12.15万股

4月13日常山药业涨8.06%，医药LOF基金重仓该股

AI赋能千行百业一线观察｜当AI让医疗器械“长出大脑”

申万宏源：26年一季报披露期临近关注创新药、CXO及上游

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news?page=6"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":719.91754,"timestamp":1776413292136,"preClose":715.96594,"halted":0,"volume":103129317,"delay":0,"changeRate":0.005519,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":3.951599,"latestTime":"04-17 16:00:00","open":715.96594,"high":728.5041,"low":704.15936,"amount":3759884233,"amplitude":0.034003,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1776389400000,1776398400000],[1776402000000,1776412800000]],"pbRate":5.639176,"peRate":-94.270914,"turnoverRate":0.00368,"increases":14,"decrements":17,"flats":2,"marketCap":460313417856,"floatMarketCap":408611897616},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":728.5041,"amplitude":0.034003,"preClose":715.96594,"low":704.15936,"pbRate":"5.639176","latestPrice":719.91754,"volume":103129317,"delay":0,"open":715.96594,"prevYearClose":556.26263,"prevWeekClose":666.249,"prevMonthClose":610.821,"prevQuarterClose":610.821,"fiveDayClose":666.249,"twentyDayClose":575.488,"sixtyDayClose":612.872,"secType":"PLATE","market":"HK","turnoverRate":0.00368,"peRate":-94.270914,"marketCap":460313417856,"floatMarketCap":408611897616,"timestamp":1776413292136,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":15,"down":15,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627413754","title":"捕捉全球医药创新机遇，借道专业工具把握“新质生产力”投资主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2627413754","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627413754?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 15:49","pubTimestamp":1776152940,"startTime":"0","endTime":"0","summary":"　　2026年政府工作报告首次将生物医药明确定位为“新兴支柱产业”，并将其纳入“十五五”规划，将其深度融入发展“新质生产力”的宏伟蓝图，这不仅是对一个行业发展的战略定位，更是对中国未来产业升级方向的清晰指引。工银瑞信基金旗下拥有一系列历经市场周期检验、聚焦医药健康领域的主题基金，为投资者布局这一“新兴支柱产业”提供了多层次、系统化的工具选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-04-14/doc-inhunavy1629906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","162414","09939","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627184954","title":"中国首个三组分百白破疫苗获批，康希诺生物成长逻辑跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2627184954","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627184954?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 15:19","pubTimestamp":1776151191,"startTime":"0","endTime":"0","summary":"盼康欣®的获批，不仅是康希诺生物产品矩阵中又一款重磅新品的落地，深层则是对公司创新技术平台厚度、管线梯度构建能力与商业化体系效率的集中验证。","market":"hk","thumbnail":"https://img2.gelonghui.com/37500-65516e94-e8c5-4b46-9002-7a60e38e1725.jpg?guru_height=853&guru_width=1280&guru_size=129556","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/37500-65516e94-e8c5-4b46-9002-7a60e38e1725.jpg?guru_height=853&guru_width=1280&guru_size=129556"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4407500","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["688185","BK1161","BK0239","06185","BK1574","159646","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627418921","title":"仿制药药企，却搭上了创新药的东风","url":"https://stock-news.laohu8.com/highlight/detail?id=2627418921","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627418921?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 15:14","pubTimestamp":1776150866,"startTime":"0","endTime":"0","summary":"就连仿制药企#津药药业，都因搭上了创新药的东风，股价接连上涨。来源：东方财富官网-津药药业 4月8日，公司发布“公司目前研发以仿制药为主，无在研创新药项目，相关炒作存在明显误读”的公告后，公司股价才有所降温。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1776132638383230835","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["159992","06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627185624","title":"心玮医疗－Ｂ(06609)股价下跌8.532%，现价港币$53.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2627185624","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627185624?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 14:55","pubTimestamp":1776149700,"startTime":"0","endTime":"0","summary":"[下跌股]心玮医疗－Ｂ(06609) 股价在下午02:55比前收市价下跌8.532%，现股价为港币$53.6。至目前为止，今日最高价为$60.3，而最低价为$53.6。总成交量为11.11万股，总成交金额为港币$617.331万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133700459_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2604141864/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2604141864/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","06609","BK1100","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627185574","title":"康方生物(09926)出现大手卖出4.8万股，成交价$138.4，涉资664.32万","url":"https://stock-news.laohu8.com/highlight/detail?id=2627185574","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627185574?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 14:53","pubTimestamp":1776149580,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在下午02:53出现大手卖出，成交量为4.8万，成交价为港币$138.4，涉资664.32万。至目前为止，股价升0.435%，今日最高价为$140.3，而最低价为$136.2，总成交量为347.994万股，总成交金额港币$4.801亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145549237_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604146536/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604146536/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2399975544.HKD","LU2476274720.SGD","IE00BPRC5H50.USD","BK1574","LU0417516738.SGD","BK1161","IE00B5MMRT66.SGD","LU0348784397.USD","LU0348766576.USD","LU1961090484.USD","LU1794554557.SGD","09926","LU2476274308.USD","LU0634319403.HKD","LU2778985437.USD","LU0348767384.USD","LU0417516571.SGD","LU2488822045.USD","LU0348825331.USD","LU0348783233.USD","LU1720050803.USD","LU0348735423.USD","LU0540923850.HKD","LU0561508036.HKD","LU0348827113.USD","LU0417516902.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627494406","title":"“明星”抗癌药中国“七连发”：跨国药企加速重塑在华商业模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2627494406","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627494406?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 13:17","pubTimestamp":1776143820,"startTime":"0","endTime":"0","summary":"近日，由阿斯利康与第一三共共同开发与商业化的德曲妥珠单抗在中国取得新突破：其序贯THP疗法用于HER2阳性早期乳腺癌新辅助治疗的适应症实现“全球首批”，中国患者成为全球最早受益于这一创新疗法的群体。这并非德曲妥珠单抗在中国的首次亮相。自2023年首次获批以来，这款被称为“大魔王”的抗体偶联药物（ADC）在中国接连拿下七项适应症，覆盖乳腺癌、肺癌、胃癌等多个领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704221860.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704221860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4080","06978","BK1574","BK4231","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627449114","title":"国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2627449114","media":"国家医保局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627449114?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 12:30","pubTimestamp":1776141000,"startTime":"0","endTime":"0","summary":"国家医保局已下发2026年定点医药机构违法违规使用医保基金典型问题清单，各地医保部门已于3月底前结合本地医保政策、诊疗项目规范，对问题清单进行细化完善。5月起，国家医保局将组织对各地自查自纠情况进行抽查复查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-04-14/doc-inhumwqc9085405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159938","159891","BK1574","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627497821","title":"加速布局儿童实体瘤治疗领域！亚盛医药 MDM2-p53 抑制剂APG-115获CDE纳入\"星光计划\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2627497821","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627497821?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 12:14","pubTimestamp":1776140040,"startTime":"0","endTime":"0","summary":"此次APG-115获纳入\"星光计划\"，将有助于公司与CDE的进一步紧密沟通，获得儿童人群研究过程中技术问题的针对性指导。APG-115此次获纳入CDE'星光计划'，是国家药监机构对该品种临床价值与研发前景的高度认可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4933478_ZH33478_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["APG","BK4017","BK4139","AAPG","LU2125909759.SGD","LU2125909916.SGD","LU1223082519.USD","06855","LU1223082196.USD","BK1161","BK4129","LU1923622291.USD","LU1223083913.SGD","BK1574","CDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627949947","title":"港股劲方医药-B盘中涨超22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627949947","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627949947?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 12:01","pubTimestamp":1776139262,"startTime":"0","endTime":"0","summary":"【港股劲方医药-B盘中涨超22%】4月14日，劲方医药-B(02595.HK)盘中涨超22%，截至发稿涨14.37%，报44.88港元，成交额1.94亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704180475.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704180475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","09939","BK1161","02595","BK1515","BK4588","VXUS","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627983499","title":"港股异动 | 绿叶制药(02186)午前涨近3% 近日自研创新药LY03020中国Ⅱ期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2627983499","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627983499?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 11:54","pubTimestamp":1776138882,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，绿叶制药午前涨近3%，截至发稿，涨2.52%，报2.85港元，成交额5323.6万港元。消息面上，近日，绿叶制药发布公告，本集团自主研发的创新药LY03020的中国Ⅱ期临床已完成首例患者入组。此前，LY03020亦已在美国获准开展临床试验，是本集团在中国和海外同步开发的又一款中枢神经系统治疗领域的创新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","02186","BK1606","BK1574","BK4588","06978","VXUS","BK1191","BK4585","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627413496","title":"数万年前的“资阳人”被爆患有牙病 四川资阳用十年造出一口好“牙”丨城市经济学","url":"https://stock-news.laohu8.com/highlight/detail?id=2627413496","media":"四川日报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627413496?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 11:05","pubTimestamp":1776135900,"startTime":"0","endTime":"0","summary":"数万年前，远古先民饱受牙病困扰；如今，在距发掘地数公里外的资阳高新区，一座“中国牙谷”正拔地而起。当地用十年时间，仿佛完成一场跨越数万年的健康回应。2016年，依托华西口腔的顶尖学科优势，经多方考察论证后，省委、省政府决定在资阳布局打造“中国牙谷”，作为全省推进供给侧结构性改革示范项目。李建直言，这是口腔企业普遍面临的生死关。资阳口腔职业学院。李建认为，口腔学院聚焦牙","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-04-14/doc-inhumsha4984083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09996","BK1583","BK1100","BK1222","09997","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627498112","title":"港股异动 | 再鼎医药(09688)涨超3% 近日与安进达成全球临床合作 Zoci正处于全球注册性临床III期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2627498112","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627498112?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 09:46","pubTimestamp":1776131184,"startTime":"0","endTime":"0","summary":"消息面上，近日，再鼎医药官微宣布，公司与安进公司达成一项全球临床研究合作，旨在评估再鼎医药处于临床阶段的靶向delta样配体3的抗体药物偶联物zocilurtatug pelitecan联合安进IMDELLTRA，一款靶向DLL3的双特异性T细胞衔接器疗法，用于治疗广泛期小细胞肺癌患者。作为该合作协议的一部分，安进将申办一项全球1b期研究，评估zoci联合IMDELLTRA在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AMGN","BK4533","BK4566","BK4548","LU2488822045.USD","BK4585","LU1057294990.SGD","IE0009355771.USD","BK1574","IE0002141913.USD","III","SG9999001440.SGD","LU0868494617.USD","BK1588","BK4526","IE00B4R5TH58.HKD","LU0109394709.USD","BK4581","LU2089984988.USD","BK1161","BK4134","IE00BFTCPJ56.SGD","LU0122379950.USD","LU0058720904.USD","LU2242646821.SGD","IE00B2B36J28.USD","BK4599","IE00BJT1NW94.SGD","VXUS","LU2242652126.USD","LU0289739699.SGD","LU2112291526.USD","LU0320765992.SGD","LU1023059063.AUD","BK4531","ZLAB","BK4139","LU2468319806.SGD","LU0889565916.HKD","LU1061106388.HKD","LU1571399168.USD","BK4534","LU1983299246.USD","BK4588","09688","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627246426","title":"归创通桥公布授出40万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2627246426","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627246426?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 07:55","pubTimestamp":1776124500,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　归创通桥（02190）发布公告，于2026年4月13日，本公司已议决根据本公司于2025年10月24日采纳的2025年股份激励计划向一名合资格参与者授出购股权，以认购合共40万股本公司H股（H股）。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-04-14/doc-inhummye4973813.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1583","02190","BK1100","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627461284","title":"谁在“裸泳”，谁有“余粮”？医械行业2025业绩加速分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2627461284","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627461284?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 07:00","pubTimestamp":1776121200,"startTime":"0","endTime":"0","summary":"2025年，“十四五”收官之年，也是集采政策全面落地、医保支付改革走向深水区的关键节点。这一年，A股医疗器械行业在挑战与机遇的夹缝中，交出了一份“冰火两重天”的成绩单：有龙头企业上市后首次遭遇营收净利“双降”，也有高端装备企业逆势实现近50%的净利增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143703511010.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143703511010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09997","09996","BK1574","BK1100","BK1583","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627557764","title":"亿腾嘉和(06998)4月13日斥资139.7万港元回购46.25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627557764","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627557764?lang=zh_cn&edition=fundamental","pubTime":"2026-04-13 21:23","pubTimestamp":1776086621,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿腾嘉和(06998)发布公告，于2026年4月13日斥资139.7万港元回购46.25万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06998","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627455433","title":"北京“创新医药32条”：突出原始创新，打通手术机器人入院堵点","url":"https://stock-news.laohu8.com/highlight/detail?id=2627455433","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627455433?lang=zh_cn&edition=fundamental","pubTime":"2026-04-13 20:45","pubTimestamp":1776084300,"startTime":"0","endTime":"0","summary":"\n                                                推动北京普惠健康保等商业健康保险覆盖更多创新药械与罕见病用药。                                                [全文]\n","market":"hk","thumbnail":"https://media.bjnews.com.cn/cover/2026/04/13/5707858776133020702.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/04/13/5707858776133020702.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1776083871129027.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1776083871129027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK1161","159938","BK1515","BK1574","09939","ROBO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627538334","title":"归创通桥(02190)4月13日耗资281.725万港元回购12.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627538334","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627538334?lang=zh_cn&edition=fundamental","pubTime":"2026-04-13 20:31","pubTimestamp":1776083491,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)公布，2026年4月13日耗资281.725万港元回购12.15万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1574","BK1583","02190","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627334734","title":"4月13日常山药业涨8.06%，医药LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627334734","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627334734?lang=zh_cn&edition=fundamental","pubTime":"2026-04-13 16:30","pubTimestamp":1776069027,"startTime":"0","endTime":"0","summary":"证券之星消息，4月13日常山药业涨8.06%，收盘报44.37元，换手率5.27%，成交量48.33万手，成交额21.29亿元。重仓常山药业的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为国泰基金的医药LOF。医药LOF目前规模为6.54亿元，最新净值0.5615，较上一交易日上涨0.52%，近一年上涨6.79%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/13/20260413807055.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/13/20260413807055.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260413/32140408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["09939","300255","159938","BK1574","BK0070","BK1515","BK0172","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627643372","title":"AI赋能千行百业一线观察｜当AI让医疗器械“长出大脑”","url":"https://stock-news.laohu8.com/highlight/detail?id=2627643372","media":"新华网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627643372?lang=zh_cn&edition=fundamental","pubTime":"2026-04-13 16:20","pubTimestamp":1776068455,"startTime":"0","endTime":"0","summary":"新华网上海4月13日电清晨，上海国家会展中心刚开馆，人流迅速涌入主通道。设备提示音、屏幕刷新声与现场讲解交织在一起，仿佛置身真实“医疗现场”。一侧，大型影像设备完成扫描后，数秒内输出结构化分析结果；另一侧，手术机器人在模拟环境中完成精细路径操作；不远处，连续血糖曲线正在实时生成并给出趋势提示。在人群密集的一角，一套非侵入式脑机接口设备前，观众围起了圈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702881466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1100","BK1574","BK1222","ARTY","CHAT","AGIX","09996","AIPO","09997","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627338194","title":"申万宏源：26年一季报披露期临近 关注创新药、CXO及上游","url":"https://stock-news.laohu8.com/highlight/detail?id=2627338194","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627338194?lang=zh_cn&edition=fundamental","pubTime":"2026-04-13 16:10","pubTimestamp":1776067851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，申万宏源发布研报称，截止至4月12日共有8家医药上市公司发布2026Q1业绩预告，其中6家利润同比增长，2家同比下滑。从细分板块来看，创新药、CXO及上游2026Q1的业绩表现有望超预期，重点推荐。从细分板块来看，创新药、CXO及上游2026Q1的业绩表现有望超预期其中，CXO板块的业绩增长主要得益于全球创新药行业景气度持续向好，行业新签订单呈现良好增长，国内外医药投融资景气度持续上行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427703.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","BK0028","BK0183","BK1147","BK0012","BK0276","BK1574","BK1564","06806","BK0188","000166","06978","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":6,"totalSize":243,"code":"91000000","status":"200"}]}}